ARCTOS medical acquired by Novartis
Basel, September 21, 2021 - Arctos Medical a Swiss start-up developing optogenetic therapies for treating blindness, is acquired by Novartis
"We are thrilled that Novartis recognizes the potential value and differentiated profile of Arctos' unique optogenetics technology," said Kostas Kaloulis, CEO of Arctos and venture partner at +ND Capital. "As a global ophthalmology leader, Novartis is ideally positioned to rapidly advance our program into the clinic. We look forward to progressing the technology to deliver transformative therapies for underserved patients."